A study to evaluate the effect of SAGE-718 on cognitive function in participants with Huntington's Disease
DIMENSION · Sage Therapeutics, Inc.
Phase 2 study testing SAGE-718 in Huntington's disease.
Recruitment endedPhase 2Not specifiedISRCTNTreatment trial
Recruiting in: United StatesExact site not listed by the study registry.
Preparing a short plain-English summary.
